Table: Brightpath Biotherapeutics -2017/18 group results

BrightPath Biotherapeutics Co

11/05/2018 08:05

May 11 (Reuters)- 
          Brightpath Biotherapeutics Co., Ltd. 
          CONSOLIDATED FINANCIAL HIGHLIGHTS 
     (in billions of yen unless specified)
                 Year ended      Year ended        Year to        NEXT   
              Mar 31, 2018    Mar 31, 2017    Mar 31, 2019      YEAR     
                 LATEST         YEAR-AGO         COMPANY       COMPANY   
                 RESULTS         RESULTS        FORECAST     H1 FORECAST 
  Sales          354 mln         529 mln         150 mln                 
               (-33.1 pct)                     (-57.7 pct)               
  Operating     loss 1.56       loss 1.11       loss 2.20                
  Recurring     loss 1.57       loss 1.12       loss 2.20                
  Net
  Net           loss 1.58       loss 1.11       loss 2.20                
  EPS        loss 41.25 yen  loss 32.74 yen  loss 52.59 yen              
  Ann Div          NIL             NIL             NIL                   
  -Q2 Div          NIL             NIL             NIL                   
  -Q4 Div          NIL             NIL             NIL                   
  
  NOTE - Brightpath Biotherapeutics Co., Ltd..
  *Second Net profit row denotes profit attributable to owners ofthe parent 
  To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4594.T